Detalhe da pesquisa
1.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997907
2.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med
; 379(23): 2220-2229, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280641
3.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med
; 378(24): 2288-2301, 2018 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863955
4.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30297397
5.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 924-937, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31122901
6.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27979383
7.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Lancet
; 387(10030): 1837-46, 2016 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26970723
8.
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
BMC Cancer
; 16: 473, 2016 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27412292
9.
A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.
Oncologist
; 20(2): 105-6, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25616430
10.
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Oncologist
; 18(2): 115-22, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23345546
11.
EGFR tyrosine kinase inhibitors: difference in efficacy and resistance.
Curr Oncol Rep
; 15(4): 396-404, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23674236
12.
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
PLoS One
; 16(2): e0246486, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534859
13.
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Clin Cancer Res
; 15(6): 2158-65, 2009 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19276291
14.
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Cancer Treat Rev
; 86: 102017, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32335505
15.
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.
Expert Rev Respir Med
; 14(2): 125-136, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31829747
16.
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
J Thorac Oncol
; 15(8): 1351-1360, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32302702
17.
Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.
Oncologist
; 14(11): 1106-15, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19897534
18.
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
N Engl J Med
; 355(24): 2542-50, 2006 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-17167137
19.
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Clin Lung Cancer
; 10 Suppl 1: S7-16, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19362948
20.
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.
Clin Lung Cancer
; 10(1): 20-7, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19289368